All In Biotech

Drug Trial Radar · NCT05909904

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

160

Actual

Start

Aug 2, 2023

Primary completion

Jun 17, 2025

Study completion Jul 23, 2026

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Jun 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Conditions

  • Head and Neck Squamous Cell Carcinoma
  • Head and Neck Cancer

Interventions

  • TislelizumabDrug

    Administered intravenously

  • BGB-A425Drug

    Administered intravenously

  • LBL-007Drug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Up to 21.2 months

Locations

73 sites in 14 countries. Site status is shown where the registry gives one.

  • Valkyrie Clinical Trials

    Los Angeles, California

  • Stanford Medicine

    Stanford, California

  • Rocky Mountain Cancer Centers, Llp(Us Oncology Research)

    Lone Tree, Colorado

  • Florida Cancer Specialist Research Institute Lake Nona

    Orlando, Florida

  • Florida Cancer Specialist Research Institute Panhandle

    Tallahassee, Florida

  • University of Kentucky Markey Cancer Center

    Lexington, Kentucky

  • Oncology and Hematology Associates of Southwest Virginia, Inc (Us Oncology Research)

    Blacksburg, Virginia

  • Cancer Care Northwest

    Spokane Valley, Washington

  • Northwest Cancer Specialist, Pc(Us Oncology Research)

    Vancouver, Washington

  • Nepean Hospital

    Kingswood, New South Wales, Australia

  • North Shore Private Hospital

    St Leonards, New South Wales, Australia

  • Gold Coast Private Hospital

    Gold Coast, Queensland, Australia

  • Greenslopes Private Hospital

    Greenslopes, Queensland, Australia

  • Cancer Research South Australia

    Adelaide, South Australia, Australia

  • Northeast Health Wangaratta

    Wangaratta, Victoria, Australia

  • St John of God, Murdoch

    Murdoch, Western Australia, Australia

  • British Columbia Cancer Agency the Vancouver Centre

    Vancouver, British Columbia, Canada

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, Canada

  • Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital

    Hefei, Anhui, China

  • Beijing Tongren Hospital, Cmu

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Sun Yat Sen University Cancer Center

    Guangzhou, Guangdong, China

  • The Tumor Hospital Affiliated to Guangxi Medical University

    Nanning, Guangxi, China

  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University Branch Donghu

    Nanchang, Jiangxi, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

  • Sichuan Cancer Hospital and Institute

    Chengdu, Sichuan, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.